Ruxolitinib cream (Opzelura) Chinese instructions for use

Ruxolitinib cream (Opzelura) is a topical targeted drug that is a Janus kinase (JAK) inhibitor and is mainly used to treat non-segmental vitiligo and mild to moderate atopic dermatitis. As an innovative topical preparation, ruxolitinib cream is the first JAK inhibitor drug approved by the FDA for the treatment of vitiligo, marking that vitiligo treatment has entered a more precise and targeted stage. The following are the Chinese instructions for use of the drug, covering indications, usage and dosage, precautions and common adverse reactions.

From the perspective of indications, ruxolitinib cream is mainly used to treat non-segmental vitiligo in people aged 12 years and above. It can also be used to treat mild to moderate atopic dermatitis. It is especially suitable for people who cannot tolerate oral systemic treatment or are not suitable for long-term use of topical hormones. In the treatment of vitiligo, it interferes with the inflammatory destruction process of melanocytes by inhibiting the JAK1 and JAK2 pathways, promoting the regeneration and distribution of melanin, and helping pigment recovery. For patients with atopic dermatitis, ruxolitinib cream can relieve symptoms such as itching, erythema, and dryness and improve skin barrier function.

In terms of usage and dosage, it is usually recommended to use ruxolitinib cream twice a day, once in the morning and once in the evening. To use, apply a thin layer of ointment to clean, dry skin and massage gently until absorbed. Each dose should not exceed 10% of the body surface area, that is, an area of u200bu200bapproximately two palms of the body, to avoid systemic overabsorption of the drug. During use, avoid the ointment coming into contact with mucous membranes such as the eyes, mouth, and nasal cavity. If you need to wash your hands after using medicine, it is recommended to wash your hands immediately after application to prevent residual medicine from accidentally contacting other parts.

In terms of precautions, when using ruxolitinib cream, avoid combining it with other topical drugs, especially products containing hormones or other immunomodulatory ingredients, to prevent drug interactions. At the same time, patients who have damage or infection in the affected area should postpone the use of this drug until the skin recovers. Long-term use should be carried out under the guidance of a doctor, especially if it is used for more than eight weeks. Regular follow-up is recommended to evaluate the efficacy and whether there are side effects. In addition, pregnant and lactating women need to be particularly cautious when using the drug. It is recommended that a doctor evaluate the pros and cons before deciding whether to use it.

Regarding adverse reactions, ruxolitinib cream is generally well tolerated, but some patients may experience local irritation reactions, such as skin redness, mild itching, stinging or dryness, etc., which are generally mild to moderate and can be relieved by themselves with prolonged use. A very small number of patients may develop acne-like dermatitis, skin infection or allergic reaction. Once persistent or worsening discomfort occurs, the drug should be discontinued immediately and consult a doctor. Theoretically, long-term use of ruxolitinib cream on a large area may cause part of the drug to be absorbed by the system, which may interfere with the bodyJAK-STATsignaling pathway, but current clinical data show that such adverse reactions are extremely rare, and more attention remains on local tolerance.

Overall, ruxolitinib cream, as a targeted topical drug, shows good efficacy and safety in the treatment of vitiligo and atopic dermatitis. Its specific usage and precautions must strictly follow the instructions and doctor's guidance. Rational use can significantly improve the treatment effect and improve the patient's quality of life. In the future, as the drug is researched on more indications and gradually launched on the market in China, it is expected to provide new treatment options for more patients with skin diseases.

Reference materials:https://www.opzelura.com/